Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

54
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
54
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

232
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
232
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

7.1K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
7.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epidemiology of Early-Onset Colorectal Cancer: A Systematic Review and Meta-Analysis of Incidence, Temporal Trends, and Associated Factors.

Cureus·2026
Same author

Comparative Diagnostic Accuracy of Cholangioscopy-Based Modalities for Indeterminate Biliary Strictures: A Systematic Review and Network Meta-Analysis.

Digestive diseases and sciences·2026
Same author

N-acetylcysteine in Thrombotic Thrombocytopenic Purpura: A Systematic Review.

Cureus·2026
Same author

Immunosuppression and vascular remodeling after liver transplantation: Mechanisms, surrogate markers, and modifiable pathways.

World journal of transplantation·2026
Same author

Safety and efficacy of efbemalenograstim alfa for chemotherapy-induced neutropenia: A systematic review and meta-analysis of randomized controlled trials.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026
Same author

Long-Term Gynecologic and Reproductive Health in Female Survivors of Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-analysis of Prevalence.

Transplantation and cellular therapy·2026

Related Experiment Video

Updated: Feb 28, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Comparative Efficacy of Complement Inhibitors in Complement Inhibitor-Naïve PNH: A Systematic Review With Supportive

Rehan Ishaque1, Abdul Subhan Talpur2, Hafiza Sidra3

  • 1Liaquat University of Medical Health & Sciences Jamshoro Pakistan.

Ejhaem
|February 26, 2026
PubMed
Summary

Complement inhibitors effectively treat paroxysmal nocturnal haemoglobinuria (PNH) by reducing haemolysis. However, direct comparisons between agents are limited due to sparse data, suggesting findings are hypothesis-generating.

Keywords:
complement inhibitorsparoxysmal nocturnal haemoglobinuria (PNH)transfusion avoidance

More Related Videos

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.3K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.4K

Related Experiment Videos

Last Updated: Feb 28, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.3K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.4K

Area of Science:

  • Hematology
  • Immunology
  • Pharmacology

Background:

  • Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, severe blood disorder.
  • It involves complement-mediated intravascular haemolysis.
  • Treatment aims to inhibit the complement system.

Purpose of the Study:

  • To compare the efficacy of available complement inhibitors in PNH patients.
  • Focus on patient-centered outcomes in individuals new to complement inhibitors.
  • Evaluate agents like ravulizumab, crovalimab, eculizumab, and pegcetacoplan.

Main Methods:

  • Systematic review and network meta-analysis following PRISMA guidelines.
  • Literature search up to May 2025 on PubMed, Cochrane CENTRAL, and ClinicalTrials.gov.
  • Frequentist model network meta-analyses conducted using a common-effects model.

Main Results:

  • Four randomized controlled trials with 589 complement inhibitor-naïve adults with PNH were included.
  • All tested agents showed benefits over placebo or supportive care for key outcomes.
  • No consistent statistically significant differences in transfusion avoidance between active treatments were found, though ravulizumab showed higher odds than crovalimab.

Conclusions:

  • Available complement inhibitors improve outcomes in PNH patients naive to these therapies.
  • The evidence network is sparse, limiting reliable inference on relative efficacy between agents.
  • Comparative findings should be considered hypothesis-generating.